Patents by Inventor Edward Thein Htun van der Horst

Edward Thein Htun van der Horst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Notch1 binding agents and methods of use thereof
    Patent number: 8834875
    Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: September 16, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventor: Edward Thein Htun Van Der Horst
  • DDR1-Binding Agents and Methods of Use Thereof
    Publication number: 20140199312
    Abstract: The present invention relates to DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The present invention further provides methods of using agents that modulate the activity of DDR1, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: January 6, 2014
    Publication date: July 17, 2014
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Edward Thein Htun Van Der Horst, Sanjeev H. Satyal
  • DDR1-binding agents and methods of use thereof
    Patent number: 8652843
    Abstract: Disclosed are DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The disclosure provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The disclosure further provides methods of using agents that modulate the activity of DDRI, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: February 18, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Edward Thein Htun Van Der Horst, Sanjeev H. Satyal
  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20130316450
    Abstract: Isolated antibodies that specifically bind the human MET Receptor and inhibit MET signaling are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of the provided MET antibodies and combinations thereof.
    Type: Application
    Filed: May 10, 2013
    Publication date: November 28, 2013
    Applicant: OncoMed Pahrmaceuticals, Inc.
    Inventors: Edward Thein Htun VAN DER HORST, Aaron Ken SATO
  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20130296536
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 7, 2013
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20130260455
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: March 1, 2013
    Publication date: October 3, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • NOTCH1 BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20130243774
    Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 19, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Edward Thein Htun van der HORST, Austin L. GURNEY, Timothy Charles HOEY, Maureen Fitch BRUHNS, Fumiko Takada AXELROD
  • Compositions and methods for diagnosing and treating cancer
    Patent number: 8455623
    Abstract: Isolated antibodies that specifically bind the human MET Receptor and inhibit MET signaling are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of the provided MET antibodies and combinations thereof.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: June 4, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Edward Thein Htun Van Der Horst, Aaron Ken Sato
  • Methods of treatment by administering antibodies to notch receptors
    Patent number: 8425903
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: April 23, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Notch-Binding Agents and Antagonists and Methods of Use Thereof
    Publication number: 20120288496
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: May 15, 2012
    Publication date: November 15, 2012
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Notch1 Binding Agents and Methods of Use Thereof
    Publication number: 20120213786
    Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.
    Type: Application
    Filed: January 13, 2011
    Publication date: August 23, 2012
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventor: Edward Thein Htun VAN DER HORST
  • Antibodies to notch receptors
    Patent number: 8226943
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: July 24, 2012
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • DDR1-Binding Agents and Methods of Use Thereof
    Publication number: 20110287011
    Abstract: Disclosed are DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The disclosure provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The disclosure further provides methods of using agents that modulate the activity of DDRI, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: August 12, 2009
    Publication date: November 24, 2011
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Edward Thein Htun Van Der Horst, Sanjeev H. Satyal
  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20110142840
    Abstract: Isolated antibodies that specifically bind the human MET Receptor and inhibit MET signaling are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of the provided MET antibodies and combinations thereof.
    Type: Application
    Filed: May 21, 2009
    Publication date: June 16, 2011
    Inventors: Edward Thein Htun Van Der Horst, Aaron Ken Sato
  • Notch-Binding Agents and Antagonists and Methods of Use Thereof
    Publication number: 20100111958
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: July 8, 2009
    Publication date: May 6, 2010
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki